X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (477014) 477014
Newspaper Article (30677) 30677
Newsletter (4184) 4184
Web Resource (1539) 1539
Book Chapter (1517) 1517
Dissertation (770) 770
Magazine Article (271) 271
Publication (215) 215
Book / eBook (141) 141
Trade Publication Article (129) 129
Conference Proceeding (113) 113
Government Document (104) 104
Book Review (33) 33
Reference (30) 30
Streaming Video (15) 15
Paper (3) 3
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (233842) 233842
animals (205238) 205238
kinases (136468) 136468
phosphorylation (100773) 100773
mice (94493) 94493
proteins (89653) 89653
oncology (87411) 87411
male (84288) 84288
biochemistry & molecular biology (79856) 79856
cell biology (78546) 78546
signal transduction (78013) 78013
apoptosis (77162) 77162
female (71510) 71510
cancer (67607) 67607
expression (66432) 66432
activation (61243) 61243
rats (57626) 57626
gene expression (53499) 53499
research (52271) 52271
cell line, tumor (50038) 50038
cells, cultured (46869) 46869
mutation (38769) 38769
research article (35667) 35667
cell line (35338) 35338
cell cycle (34950) 34950
signal transduction - drug effects (34586) 34586
analysis (34006) 34006
pharmacology & pharmacy (33466) 33466
multidisciplinary sciences (33144) 33144
enzyme inhibitors - pharmacology (32667) 32667
cells (31600) 31600
tumors (31054) 31054
medicine (31042) 31042
neurosciences (30758) 30758
inhibition (30687) 30687
physiological aspects (29716) 29716
protein kinases (29255) 29255
genetic aspects (28259) 28259
rodents (28240) 28240
middle aged (28009) 28009
cell proliferation (27251) 27251
health aspects (27215) 27215
physiology (26601) 26601
kinase (26489) 26489
apoptosis - drug effects (26476) 26476
inflammation (26472) 26472
biology (26403) 26403
science (24596) 24596
gene-expression (24163) 24163
metastasis (24012) 24012
adult (23688) 23688
protein kinase inhibitors - pharmacology (23588) 23588
growth (23486) 23486
immunology (23419) 23419
oxidative stress (22683) 22683
aged (22153) 22153
blotting, western (21822) 21822
dose-response relationship, drug (21721) 21721
studies (21677) 21677
care and treatment (21566) 21566
medicine, research & experimental (21514) 21514
protein (20954) 20954
cell growth (20804) 20804
cell proliferation - drug effects (20543) 20543
in-vitro (20249) 20249
proliferation (20181) 20181
rats, sprague-dawley (20075) 20075
antineoplastic agents - pharmacology (19876) 19876
chemotherapy (19711) 19711
cancer therapies (19448) 19448
genes (19354) 19354
enzymes (19308) 19308
hematology (18724) 18724
mice, inbred c57bl (18712) 18712
breast cancer (18393) 18393
metabolism (18217) 18217
protein-kinase (18210) 18210
protein-serine-threonine kinases - metabolism (18178) 18178
pathway (18118) 18118
biochemistry (18084) 18084
enzyme activation (18055) 18055
signal transduction - physiology (17906) 17906
protein-kinase-c (17816) 17816
cytokines (17764) 17764
protein binding (17763) 17763
time factors (17642) 17642
phosphorylation - drug effects (17534) 17534
immunohistochemistry (17204) 17204
activated protein-kinase (17081) 17081
nf-kappa-b (16900) 16900
map kinase (16760) 16760
transfection (16694) 16694
inhibitors (15960) 15960
in-vivo (15935) 15935
receptor (15893) 15893
tumor cells, cultured (15877) 15877
molecular sequence data (15617) 15617
protein kinase c - metabolism (15612) 15612
medical research (15586) 15586
transcription factors (15444) 15444
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (72) 72
Gerstein Science - Stacks (34) 34
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
Chemistry (A D Allen) - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (512148) 512148
Japanese (2966) 2966
Chinese (2710) 2710
French (1141) 1141
German (1034) 1034
Russian (598) 598
Portuguese (313) 313
Spanish (251) 251
Korean (203) 203
Polish (162) 162
Norwegian (86) 86
Czech (85) 85
Hungarian (78) 78
Italian (63) 63
Dutch (57) 57
Turkish (33) 33
Ukrainian (29) 29
Danish (22) 22
Swedish (19) 19
Croatian (13) 13
Slovak (12) 12
Finnish (10) 10
Hebrew (6) 6
Bulgarian (4) 4
Romanian (4) 4
Serbian (4) 4
Slovenian (4) 4
Latin (3) 3
Persian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Malay (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Methods in molecular biology, ISBN 1617793361, Volume 795., xi, 256
Book
Cellular and molecular life sciences : CMLS, ISSN 1420-9071, 2015, Volume 73, Issue 5, pp. 985 - 1001
Journal Article
Nature reviews. Cancer, ISSN 1474-1768, 2017, Volume 17, Issue 2, pp. 93 - 115
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
CA: a cancer journal for clinicians, ISSN 0007-9235, 2010, Volume 60, Issue 4, pp. 222 - 243
... Because angiogenesis is a key process in tumor growth, and a limited process in healthy adults, developing angiogenesis inhibitors is a desirable anticancer target for which few... 
TYROSINE KINASE INHIBITORS | CELL LUNG-CANCER | PHASE-III TRIAL | FARNESYL-PROTEIN TRANSFERASE | FACTOR 1-ALPHA | ONCOLOGY | ENDOTHELIAL-GROWTH-FACTOR | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | FACTOR EXPRESSION | VASCULAR-PERMEABILITY FACTOR | TUMOR-GROWTH | Neoplasms - metabolism | Nucleic Acid Synthesis Inhibitors - pharmacology | Humans | Receptor Protein-Tyrosine Kinases - physiology | Antibodies, Monoclonal - therapeutic use | Receptors, Notch - antagonists & inhibitors | Protein Binding - drug effects | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Neovascularization, Pathologic - prevention & control | Farnesyltranstransferase - antagonists & inhibitors | Thioredoxins - antagonists & inhibitors | Nucleic Acid Synthesis Inhibitors - therapeutic use | Basic Helix-Loop-Helix Transcription Factors - physiology | Antibodies, Monoclonal - pharmacology | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Receptors, Notch - physiology | Neoplasms - blood supply | Basic Helix-Loop-Helix Transcription Factors - antagonists & inhibitors | Neoplasms - drug therapy | Signal Transduction - drug effects | Cell Transformation, Neoplastic | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Intracellular Signaling Peptides and Proteins - physiology | Complications and side effects | Care and treatment | Ligands (Biochemistry) | Physiological aspects | Development and progression | Dosage and administration | Angiogenesis inhibitors | Neovascularization | Identification and classification | Growth factors | Cancer | Angiogenesis | Pharmacology | FDA approval | Drug therapy | Kinases | Tumors | hypoxia inducible factor (HIF) | kinase inhibitors | growth factors | angiogenesis inhibitors | VEGF | anti-angiogenesis
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 19, pp. 2193 - 2202
.... We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or cediranib combinations are tolerable and active in recurrent women's cancers... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2015, Volume 125, Issue 5, pp. 1780 - 1789
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases... 
MEDICINE, RESEARCH & EXPERIMENTAL | ONCOGENIC ACTIVATION | PROTEIN-KINASE | TUMOR-INFILTRATING MACROPHAGES | ADAPTIVE RESISTANCE | ACQUIRED-RESISTANCE | CLINICAL RESISTANCE | DIACYLGLYCEROL KINASES | RECEPTOR TYROSINE KINASE | IMATINIB MESYLATE | ANTITUMOR EFFICACY | Immunotherapy - methods | Apoptosis - drug effects | Humans | Substrate Specificity | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms - genetics | Protein Processing, Post-Translational - drug effects | Drug Design | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Molecular Targeted Therapy - methods | Neoplasms - enzymology | Gene Fusion | Enzyme Activation - drug effects | Neoplasms - drug therapy | Drug Synergism | Point Mutation | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Oncogene Proteins, Fusion - antagonists & inhibitors | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Enzyme inhibitors | Physiological aspects | Research | Drug therapy | Phosphotransferases | Health aspects | Cancer | Proteins | Phosphorylation | Gene amplification | Biology | Regulation | Genomes | Mutation | Metastasis | Kinases | Phosphatase | Tumors | Review
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 06/2018, Volume 19, Issue 3, pp. 345 - 361
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4... 
CELL LUNG-CANCER | CUTANEOUS ADVERSE EVENTS | UNTREATED MELANOMA | METASTATIC MELANOMA | ANTI-PD-1 THERAPY | IPILIMUMAB THERAPY | PREEXISTING AUTOIMMUNE DISORDERS | JAVELIN SOLID TUMOR | OF-THE-LITERATURE | NIVOLUMAB THERAPY | DERMATOLOGY | Index Medicus
Journal Article
Journal Article